InvestorsHub Logo
Followers 32
Posts 6922
Boards Moderated 0
Alias Born 12/07/2003

Re: subslover post# 3631

Wednesday, 05/20/2015 11:30:39 AM

Wednesday, May 20, 2015 11:30:39 AM

Post# of 7724
Yup and here might be why...

7:30 am Today, May 20, J&J / Janssen Press Release Highlight Re: Geron's Imetelstat
"At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) will announce plans to file for regulatory approval of more than 10 new products between 2015 and 2019, each with the potential to exceed $1 billion in revenue1, as well as more than 40 line extensions of existing and new medicines.

Late-stage products expected to drive growth in the next several years, following regulatory approvals, include daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; ..."

"evil flourishes when good people fail to act"

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News